Edition:
United States

Morphosys AG (MORG.DE)

MORG.DE on Xetra

75.05EUR
11:35am EST
Change (% chg)

€-0.20 (-0.27%)
Prev Close
€75.25
Open
€74.70
Day's High
€75.40
Day's Low
€74.30
Volume
51,863
Avg. Vol
153,733
52-wk High
€87.35
52-wk Low
€49.63

Latest Key Developments (Source: Significant Developments)

Morphosys And Galapagos Present Results From Phase 1 Study With Mor106
Monday, 19 Feb 2018 03:04am EST 

Feb 19 (Reuters) - MORPHOSYS AG ::SAID ON SATURDAY MORPHOSYS AND GALAPAGOS PRESENT RESULTS FROM A PHASE 1 STUDY WITH MOR106 IN ATOPIC DERMATITIS AS LATE-BREAKING ABSTRACT.IN THE STUDY, MOR106 WAS GENERALLY WELL TOLERATED IN ATOPIC DERMATITIS(AD)PATIENTS.83% OF PATIENTS (5 OUT OF 6) AT THE HIGHEST DOSE REACHED AT LEAST 50% IMPROVEMENT PER THE ATOPIC DERMATITIS AREA AND SEVERITY INDEX (EASI-50) AT WEEK 4.POOLED DATA ACROSS ALL DOSE COHORTS SHOWED 72% IMPROVEMENT OF AD SYMPTOMS AT WEEK 12 COMPARED TO BASELINE IN PATIENTS TREATED WITH MOR106.PHASE 2 DEVELOPMENT OF MOR106 PLANNED TO BE INITIATED IN FIRST HALF OF 2018.  Full Article

Morphosys Says Licensee Janssen Receives Approval For Tremfya In Canada
Tuesday, 5 Dec 2017 01:30am EST 

Dec 5 (Reuters) - MORPHOSYS AG ::DGAP-NEWS: MORPHOSYS ANNOUNCES THAT ITS LICENSEE JANSSEN HAS RECEIVED APPROVAL FOR TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA.MORPHOSYS IS ELIGIBLE TO RECEIVE ROYALTIES ON NET SALES OF TREMFYA.  Full Article

Morphosys Increases Financial Guidance For 2017
Thursday, 30 Nov 2017 05:02am EST 

Nov 30 (Reuters) - MORPHOSYS AG ::INCREASES FINANCIAL GUIDANCE FOR 2017 FOLLOWING SIGNATURE OF REGIONAL LICENSE AGREEMENT FOR ANTIBODY MOR202 WITH I-MAB.‍FOR YEAR 2017, MORPHOSYS NOW EXPECTS REVENUES IN RANGE FROM EUR 63 TO 66 MILLION​.NOW EXPECTS FY EBIT OF EUR -66 TO -71 MILLION (UP FROM PREVIOUSLY EUR -75 TO -85 MILLION).FY ‍PROPRIETARY RESEARCH AND DEVELOPMENT EXPENSES WILL BE IN RANGE FROM EUR 96 TO 100 MILLION (PREVIOUSLY EUR 85 TO 95 MILLION)​.RECEIVES AN IMMEDIATE UPFRONT PAYMENT OF USD 20 MILLION FROM LICENSE AGREEMENT SIGNED.WILL BE ENTITLED TO RECEIVE ADDITIONAL MILESTONE PAYMENTS FROM I-MAB OF UP TO C. USD 100 MILLION.TO BE ENTITLED TO RECEIVE TIERED, DOUBLE-DIGIT ROYALTIES ON NET SALES OF MOR202 IN TERRITORY.SHARES JUMP 5.2 PERCENT​.  Full Article

Janssen receives approval for Tremfya in Europe - Morphosys
Thursday, 23 Nov 2017 04:19am EST 

Nov 23 (Reuters) - Morphosys AG :Announces that its licensee Janssen has received approval for Tremfya(r) (guselkumab) in Europe for the treatment of moderate-to-severe plaque psoriasis.Says is ‍entitled to royalties on net sales of Janssen's Tremfya​.  Full Article

Morphosys Q3 revenue up 20 pct at 15 mln eur​
Tuesday, 7 Nov 2017 01:09am EST 

Nov 7 (Reuters) - Morphosys AG :Q3 net loss -24 million eur versus -12.8 million eur loss year ago.Q3 revenue rose 20 percent to 15 million eur.Says ‍group revenue for q3 2017 up 20% to eur 15.0 million (q3 2016: eur 12.5 million)​.Says Dr. Markus Enzelberger, interim CSO, now appointed CSO​.Says ‍company confirms financial guidance​.Says ‍earnings before interest and taxes (ebit) in q3 2017 amounted to eur -23.5 million (q3 2016: eur -13.1 million)​.  Full Article

Morphosys says received FDA breakthrough therapy designation for its antibody MOR208 in Relapsed/Refractory DLBCL
Monday, 23 Oct 2017 04:25pm EDT 

Oct 23 (Reuters) - Morphosys AG -:DGAP-Adhoc: Adhoc: Morphosys receives FDA breakthrough therapy designation for its antibody MOR208 in Relapsed/Refractory DLBCL.Morphosys AG says ‍receives FDA breakthrough therapy designation for its antibody MOR208 in relapsed/refractory DLBCL​.  Full Article

Morphosys says to receive milestone payments from Janssen
Thursday, 21 Sep 2017 01:30am EDT 

Sept 21 (Reuters) - Morphosys AG :Says announces that its licensee Janssen has initiated two phase 3 studies with TremfyaTM (guselkumab) in psoriatic arthritis.Says will receive a milestone payment from Janssen in connection with start of phase 3 development in PSA.Says financial details were not disclosed.  Full Article

Morphosys confirms FY 2017 guidance
Tuesday, 5 Sep 2017 04:45am EDT 

Sept 5 (Reuters) - MORPHOSYS AG ::FINANCIAL GUIDANCE FOR FY 2017 RE-CONFIRMED.  Full Article

Morphosys affirms guidance after Q2 results
Thursday, 3 Aug 2017 01:00am EDT 

Aug 3 (Reuters) - Morphosys Ag :dgap-news: morphosys reports significant progress in its therapeutic programs in second quarter of 2017.Says in Q2 of 2017, group revenues amounted to eur 11.7 million, comparable with revenue level in Q2 2016 (eur 12.2 million)..Says proprietary development segment recorded revenues of eur 0.3 million (Q2 2016: eur 0.2 million)..Says in partnered discovery segment Q2 revenues reached eur 11.5 million (Q2 2016: eur 12.0 million)..Says group EBIT in Q2 2017 amounted to eur -15.4 million (q2 2016: eur -9.5 million).Says continues to expect group revenues in range of eur 46 to 51 million.Says research and development expenses for proprietary drug development and technology development are confirmed to be in a corridor of eur 85 to 95 million..Says guidance for earnings before interest and taxes (EBIT) continues to be in range from eur -75 to -85 million.  Full Article

Morphosys CEO sees 5 months of guselkumab royalties this year
Friday, 14 Jul 2017 05:23am EDT 

July 14 (Reuters) - Morphosys CEO tells Reuters:Says he expects royalties for 5 months this year after U.S. Approval of guselkumab.Says milestone payment for guselkumab approval is included in FY guidance, royalties are not.  Full Article

BRIEF-Morphosys Announces New Data On Tremfya

* DGAP-NEWS: MORPHOSYS ANNOUNCES THAT TREMFYA(R) (GUSELKUMAB) DATA DEMONSTRATED LONG-TERM SKIN CLEARANCE IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS Source text for Eikon: Further company coverage: